| 영문 | platelet | 한글 | 혈소판 |
|---|---|---|---|
| 설명 | 골수의 거대 세포인 거대핵세포의 세포질 일부가 떨어져서 순환 혈액 중에 출현한 것으로 직경이 2~4μm의 작은 과립체이다. 혈소판은 손상을 입은 혈관의 노출된 결합 조직에 붙어 여러 물질을 분비하여 지혈 및 혈액 응고에 중요한 역할을 한다. |
||
| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| 영문 | connective tissue | 한글 | 결합조직 |
|---|---|---|---|
| 설명 | 체내에 널리 분포하며, 장기, 조직사이를 메우고 그것을 기계적으로 지지, 조직이다. 그밖에 혈관, 림프관, 신경을 인도하며 영양, 대사산물의 수송 또는 저류, 나아가서는 손상, 감염에 대한 방어 또는 수복 등에도 작용한다. 결합조직은 세포간질이 풍부하며, 세포간질을 구성하는 기질과 섬유의 성상에 따라 간엽조직, 섬유성 결합조직(성긴섬유성 결합조직, 촘촘한 섬유성 결합조직), 지방조직, 탄성조직, 세망 조직 등으로 분류된다. |
||
| PAF | paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl... |
|---|---|
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| TF | free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ... |
| PA | panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'... |
| PDGF | Anti-platelet-derived growth factor |
|---|---|
| PAF | L-platelet-activating factor |
| lyso-PAF | Lyso platelet activating factor |
| PDGF BB | Platelet Derived Growth Factor |
| PDGF(B) | Platelet Derived Growth Factor B |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
acute angle
| platelet tissue factor | <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin). (18 Nov 1997) |
|---|
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
|---|---|
| platelet-activating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet-aggregating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet-derived growth factor | <growth factor> The major mitogen in serum for growth in culture of cells of connective tissue origin. It consists of 2 different but homologous polypeptides A and B (~30,000 D) linked by disulphide bonds. Believed to play a role in wound healing. It is carried in the alpha-granules of platelets and is released when platelets adhere to traumatised tissues. Connective tissue cells near the traumatised region respond by initiating the process of replication. The B chain is almost identical in sequence to p28sis, the transforming protein of simian sarcoma virus, that can transform only those cells that express receptors for platelet derived growth factor, suggesting that transformation is caused by autocrine stimulation. The receptor is a tyrosine kinase. Acronym: PDGF (12 Dec 1998) |
| platelet factor 3 | <haematology> Phospholipid associated with the platelet plasma membrane that contributes to the blood clotting cascade by forming a complex (thromboplastin) with other plasma proteins and activating prothrombin. (31 Dec 1997) |
| platelet factor 4 | <haematology> Platelet released protein that promotes blood clotting by neutralising heparin. (31 Dec 1997) |
| low affinity platelet factor IV | Cytokine, produced from platelet basic protein, that acts as a growth factor. (18 Nov 1997) |
| tissue factor | <cell biology> Integral membrane glycoprotein of around 250 residues, that initiates blood clotting after binding factors VII or VIIa. (18 Nov 1997) |
| tissue weighting factor | In radiation protection, a factor weighting the equivalent dose in a particular tissue or organ in terms of its relative contribution to the total deleterious effects resulting from uniform irradiation of the whole body. See: effective dose. (05 Mar 2000) |
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| medication, anti-platelet | Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| platelet | <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels. Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation. Synonym: thrombocytes. (09 Oct 1997) |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|